about
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerProspective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabBRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerHistopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.Biomarker in Colorectal Cancer.Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.First-line chemotherapy for mCRC—a review and evidence-based algorithm.TAS-102 for the treatment of metastatic colorectal cancer.Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab.Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.The role of tumor angiogenesis as a therapeutic target in colorectal cancer.The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.Immunotherapy in Gastrointestinal Cancers.The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer
P50
Q27853212-79EEACE6-ACEC-4803-8711-6BB9AA406DD3Q30855372-56871901-0C89-4F5A-98DB-5E8AA8F06AA9Q34806780-7FD0FBEF-E3BA-48D7-B24E-E57D97F1BFBFQ34825323-9B598CFF-0A10-40DF-BC66-C7F98EAFF7A1Q36086837-0C718276-DF48-4047-AE71-57776363C85BQ36472959-A5202FDB-CF9F-407F-85E4-890B3332AEE3Q36706109-3934F0CD-A79B-4CA6-BB15-F9C5D7B3E01AQ36959113-1C205581-8946-4508-B1A6-7445DAF47223Q37075302-BA98DAFF-C459-4A01-BC3F-25EF2FA206F4Q37114675-BA5660F4-8676-4A32-BD5D-2950E3957012Q37619811-B23F8A5A-E902-4C8D-9A84-93494500F344Q37832504-D2E706F1-F6D1-4159-916B-C395EFAD306BQ38555200-F82C7D72-A7C9-4CE7-BE9E-DFB29C4CB726Q38618169-E4074C2A-AA42-4AE9-A486-22FBB73DAFF6Q38650454-DC0A5932-732F-41D3-9DC0-CDBF07DD09CCQ41562027-08301ED0-767F-4A9A-B702-CCC4B969EDA3Q42813995-57F9D104-9DF9-43C4-B991-DDD789E7EBCAQ43649036-596929D7-299C-4857-A375-1ED2AB276679Q44995693-486BE862-0AB6-46B1-B731-CB652E7F9C90Q45975984-78F30409-29EF-4E36-87B9-983C50BEDE48Q46007790-3FE593F2-8704-4E58-B8BE-8BE5B6270EF0Q46050934-682366FA-065B-4A57-B38F-3FA1D86C6429Q46099008-83B40A7A-E464-4B34-A572-A7A559F3D785Q46173361-C21C8336-9AA4-441F-BF24-30D63E1B50B5Q46253386-1B49A039-0DFA-45AE-99F7-BE90985D964FQ46300809-98FCB115-9D8F-491A-ABCB-089B0D4DC913Q46301372-49382CFA-0C08-445F-AAD5-181B1FDC8AACQ46473711-532991AC-E6C9-4BB6-9F43-D9C2766DBF57Q46642125-FD3E0B75-40EB-4883-B953-A05B7B4EA3BDQ46713797-4F6BFD61-3528-4462-9A43-895BDBE49444Q47729622-F70C9114-4197-4C7E-81BA-7B181E813796Q48523391-BB5473EA-9BF2-4AD9-8159-49F7DA6261AAQ50862095-FA27BDE4-0A62-4A8D-9CEA-2B880634308FQ52595509-5BD5E1B0-15E1-498D-9852-49145B2AB97FQ52659461-C02CB7F1-514D-4F38-B27E-A69F3EDB518CQ52664398-F578435E-5D1A-491C-BE74-9766B6830BE9Q52722442-187AE83C-A541-4CD4-8EC6-68961E7437D6Q53183990-83691A7E-C356-4559-BD2F-7DEE32F5B8CBQ53558675-15448EA2-7A4E-404C-B89A-5C30FE67AF6AQ57424151-8DAB14FA-B002-4AEA-B185-E0B2B888309C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marta Schirripa
@ast
Marta Schirripa
@en
Marta Schirripa
@es
Marta Schirripa
@nl
Marta Schirripa
@sl
type
label
Marta Schirripa
@ast
Marta Schirripa
@en
Marta Schirripa
@es
Marta Schirripa
@nl
Marta Schirripa
@sl
prefLabel
Marta Schirripa
@ast
Marta Schirripa
@en
Marta Schirripa
@es
Marta Schirripa
@nl
Marta Schirripa
@sl
P106
P1153
37017394600
P21
P31
P496
0000-0001-8316-4411